Research Square
LiteVax-adjuvanted influenza vaccine induces transient interferon-driven innate activation and accelerates early IgG3 responses in older adults
By Valentino D’Onofrio, Marjolein Verstraete, Sharon Porrez, Show 14 more authorsIsabel Leroux-Roels
Preprint: non-randomised trial in 56 peopleInterventions
Abstract
Vaccine immunogenicity declines with age due to immunosenescence, underscoring the need for improved adjuvants. LiteVax Adjuvant (LVA), a squalane-in-water emulsion containing carbohydrate fatty-acid monosulphate esters, has shown potential to enhance influenza vaccine responses, but its mechanisms in humans remain unclear.
- Litevax adjuvant
- Quadrivalent influenza vaccine
- Immune response
- Type I interferon signalling
- Influenza
- Humans
The paper
Ghent University
Research Square, 3 Aug 2026, CC BY, Preprint, not peer-reviewed
